Rebamipide Dosage for Gastrointestinal Conditions
The standard dosage of rebamipide for adult patients with gastritis or gastric ulcers is 100 mg orally three times daily.
Standard Dosing Regimen
Rebamipide 100 mg three times per day is the established therapeutic dose for gastric ulcers and gastritis, administered continuously for 8-12 weeks depending on the indication 1, 2, 3.
The medication should be taken three times daily at regular intervals to maintain consistent mucosal protection throughout the day 4.
Treatment Duration by Indication
Gastric Ulcers (NSAID-induced or H. pylori-related)
8 weeks of treatment is the standard duration for healing gastric ulcers, with this regimen showing complete healing in most patients 1.
For prevention of NSAID-induced gastropathy in patients requiring continuous NSAID therapy, 12 weeks of rebamipide 100 mg three times daily demonstrated efficacy comparable to misoprostol with better tolerability 3.
Chronic Gastritis
- 26 weeks (6 months) of rebamipide 100 mg three times daily significantly improved clinical symptoms, gastric mucosal lesions, and reduced progression to intestinal metaplasia in chronic gastritis patients 2.
Formulation Options
Rebamipide is bioequivalent in both tablet (100 mg) and granule (20%/0.5g) formulations, with identical pharmacokinetic profiles 4.
The granule formulation may be preferred for patients with dysphagia or difficulty swallowing tablets, as it provides the same therapeutic effect with easier administration 4.
Special Clinical Scenarios
Post-Endoscopic Submucosal Dissection (ESD)
Combination therapy with rebamipide 300 mg daily plus rabeprazole 20 mg daily for 8 weeks achieved 86.7% complete healing of artificial ulcers after ESD, compared to only 54.8% with PPI monotherapy 5.
This combination is particularly effective in patients with severe atrophic gastritis (92.9% healing rate versus 30.0% with PPI alone) 5.
Mechanism and Safety Profile
Rebamipide works through multiple gastroprotective mechanisms: stimulating prostaglandin and mucus glycoprotein synthesis, inhibiting reactive oxygen species, and reducing inflammatory cytokines 1.
Adverse effects are minimal, with significantly better gastrointestinal symptom tolerability compared to misoprostol, resulting in lower dropout rates (10.3% versus 18.6%) 3.
The medication demonstrates excellent safety and patient satisfaction across all studied populations, with few reported adverse effects 1, 2.
Clinical Pearls
Do not reduce the dose below 100 mg three times daily, as this is the established therapeutic dose validated in multiple clinical trials 1, 2, 3.
Rebamipide is particularly advantageous for NSAID users, showing significant improvement in gastric inflammation scores and superior symptom control compared to other gastroprotective agents 1, 3.
Consider extended therapy (26 weeks) for chronic gastritis when the goal is to prevent premalignant progression to intestinal metaplasia 2.